Turbine is virtualizing biological experiments with AI to accelerate drug discovery and improve clinical translatability. Using its foundational virtual cell model powered by its lab-in-the-loop, Turbine creates virtual copies of experimental assays. Running experiments at computational speed and scale allows researchers to test millions of ideas, beyond physical lab constraints, to understand biological drivers of disease. Working with scientists at leading biopharma like MSD (Merck & Co.), AstraZeneca and Bayer, Turbine’s virtual assays have rationalized experiments across more than 30 discovery programs. Backed by leading tech and industry investors like Accel, MSD Global Health Innovation Fund, Interactive Venture Partners and Beiersdorf, Turbine is turning biology into an engineering discipline.
Taiwan Universe BioMedicine
Innovative platform of enterovirus and influenza VLP vaccines. – Promising option to combat viruses mutation – Provide a broad-spectrum prevention with better immunogenicity – Enable faster scaling-up
Suven Life Sciences Limited
Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in CNS disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer’s disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson’s disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer’s type (Global Phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; Phase-2 study for Cataplexy and pivotal Phase-3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase-2a study completed; Double blind randomized Placebo controlled Phase-2b study ongoing); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study in progress). In addition to these clinical assets, we have 7 projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major markets.
Sussex Research Laboratories Inc.
Sussex Research Laboratories Inc. (Ottawa, Canada) is a globally recognized specialist in empowering therapeutic innovation through glycoscience. The company applies its expertise in glycodesign, glycan and glycoconjugate synthesis, and linker chemistries across a wide range of therapeutic areas, including vaccine development, protein and antibody engineering, and targeted drug delivery. With 30 years of experience as a Contract Research & Development (CRO) service provider, Sussex Research supports pharmaceutical and biopharmaceutical partners in applying glycotechnology to next-generation therapeutics, including oligonucleotide, peptide, protein, lipid, and small-molecule modalities, as well as lipid nanoparticle (LNP) technologies for modern drug design and delivery. The company is also widely recognized for its enabling product portfolio of advanced glycans, glycopeptides, glycoconjugates, and targeting ligand/linker systems.
SpeciLife Inc
SpeciLife is a biospecimen sourcing hub supporting pharma and biotech teams in translational and preclinical research. We provide access to high-quality, well-annotated human samples (FFPE, fresh and frozen tissues, biofluids, and cells) through established partnerships with a global network of hospitals, clinical centers, and biobanks. Our approach is collaborative and science-driven, with our internal scientific team closely involved in feasibility assessment, quality oversight, and study alignment. We support projects across key therapeutic areas including oncology, autoimmune, infectious, and neurodegenerative diseases.
Simpson Biotech Co., Ltd.
Simpson Biotech Co., Ltd. (SBC), a private Co. founded in 1998, located in Taiwan is focusing on: (I). Medicinal fungus fermentation & enzymatically hydrolyzed bioactive natural ingredients used for dietary supplements, cosmetics & drug discovery. (II). OEM/ODM services for Recombinant Proteins (i.e. Industrial Enzymes), using a patented starch-binding protein as the affinity tag. New product launched in 2023: 1. Antrodia cinnamomea extract as natural ingredient for cosmetics formulation, 2. Potent anti-yeast & anti-bacteria soluble chitosan for food/drug & agriculture applications; 2. World’s first high purity (chitobiose+chitotriose > 90%) oligo chitosan for weight, diabetes and triglyceride control; 3. Hydrolyzed Fucoidan for immune & glucose control. SBC has won numerous awards with 54 patents issued. —–>—– 【Natural Compound as Oral Drug development for NAFLD/NASH】 Reduce liver triglyceride and cholesterol in NAFLD Reduce serum triglyceride and cholesterol in NAFLD Reduce liver fat deposition in NAFLD Reduce ALT and AST in NAFLD Anti-inflammation and oxidative stress Anti-fibrosis US, CN, TW patents granted 【Recombinant Protein Expression/Purification Platform (HERPEPSTM) and Products】 Patent Recombinant Protein Platform & CDMO Service – Cost-effective recombinant protein expression & purification system; From gene to protein Starch Binding Protein (SBP) as an affinity tag One-step purification of recombinant protein by starch Protein immobilization on starch enhanced the thermostability & shelf life Easy to scale up: From 100L lab-scale concept proof to 8000L mass production Ideal for industrial, food, feed enzymes Self-owned Tool Box for Protein Expression in Pichia pastoris Methanol-induced or Methanol-free expression Antibiotics-free expression host Genetic manipulation of expression strain with high yield Cost can be 12%) of Simpson Biotech’s currently marketed dietary supplement actually illustrates both the safety and the effectiveness of the mycelia and the compound of Hepasim® through human clinical studies. One clinical study for Rheumatoid Arthritis (RA) has been completed. Initial results from the clinical study plus the previous metabolic/pharmacokinetic animal studies on these compounds already illustrate that Hepasim® is a promising NCE drug candidate. 【Fermented natural products for dietary supplement】 Alcoholic Hangover Release : Antrodia cinnamomea mycelia Neuroprotective & Memory Enhancement : Ginsenoside compound K Immune Regulation : Cordyceps sinensis mycelia, Hydrolyzed Fucoidan Male Hormone (Testosterone) Stimulant : Cordyceps sinensis mycelia Heart Protection : Agaricus blazei murill Increase Stamina : low molecular weight functional peptides from casein, whey, soy, collagen, silk OEM/ODM Fermentation : Cordyceps sinensis, Phellinus linteus, Ganoderma lucidum, Agaricus blazei murill and other mycelia and their extracts Fermented Vegetables & Grains Concentrate as prebiotics Cosmetics for skin whitening & anti-scar : Antrodia cinnamomea extract 【Immune booster for IFN-γ stimulation as anti-viral and antibiotic alternative feed additive】 LZ-8 is a fungal immunomodulatory protein originally isolated from the popular oriental medicinal fungus. Oral administration of rLZ-8 stimulates IFN-γ secretion. It is not only a good dietary supplement for humans but also an antibiotic alternative for animal additives for the prevention of virus or coccidia infection in field studies. Possible pharmaceutical applications per oral include immune-regulatory diseases. IFN-γ Stimulant Anti-viral Antibiotic alternative Anti-coccidia Increase feed efficiency US, TW, CN patent granted (US9950028, I589586, CN106232133A) | Simpson Biotech Co., Ltd. (SBC), a private Co. founded in 1998, located in Taiwan is focusing on: (I). Medicinal fungus fermentation & enzymatically hydrolyzed bioactive natural ingredients used for dietary supplements, cosmetics & drug discovery. (II). OEM/ODM services for Recombinant Proteins (i.e. Industrial Enzymes), using a patented starch-binding protein as the affinity tag and in-house non-methanol, antibiotics-free expression strain. Highlight in 2024: 1. Recombinant protein OEM/ODM with proprietary yeast platform, 2. Antrodia cinnamomea extract as natural ingredient for cosmetics formulation. 3. Antrodin as potent oral drug for NAFLD/NASH; 4. Natural anti-yeast & anti-bacteria soluble chitosan for food/drug & agriculture applications; SBC has won numerous awards with 54 patents issued. —–>—– 【Recombinant Protein OEM/ODM with Proprietary Yeast Platform】 – One-step purification of recombinant protein by starch – Protein immobilization on starch enhanced the thermostability & shelf life – Easy to scale up: From 100L lab-scale concept proof to 8000L mass production – Ideal for industrial, food, feed enzymes – Turn-key licensed(non-exclusive) to global feed company already > – In-house Non-Methanol promoter compared to AOX1 – Antibiotics-free expression strain: Eco-friendly – Genetic manipulation of expression strain with high yield – Cost can be 12%) of Simpson Biotech’s currently marketed dietary supplement actually illustrates both the safety and the effectiveness of the mycelia and the compound of Hepasim® through human clinical study for Rheumatoid Arthritis (RA). – Initial results from the clinical study plus the previous metabolic/pharmacokinetic animal studies on these compounds already illustrate that Hepasim® is a promising NCE drug candidate. 【Fermented natural products for dietary supplement】 – Alcoholic Hangover Release : Antrodia cinnamomea mycelia – Neuroprotective & Memory Enhancement : Ginsenoside compound K – Immune Regulation : Cordyceps sinensis mycelia, Hydrolyzed Fucoidan – Male Hormone (Testosterone) Stimulant : Cordyceps sinensis mycelia – Heart Protection : Agaricus blazei murill – Increase Stamina : low molecular weight functional peptides from casein, whey, soy, collagen, silk – OEM/ODM Fermentation : Cordyceps sinensis, Phellinus linteus, Ganoderma lucidum, Agaricus blazei murill and other mycelia and their extracts – Fermented Vegetables & Grains Concentrate as prebiotics – Cosmetics for skin whitening & anti-scar : Antrodia cinnamomea extract 【Immune booster for IFN-γ stimulation as anti-viral and antibiotic alternative feed additive】 LZ-8 is a fungal immunomodulatory protein originally isolated from the popular oriental medicinal fungus. Oral administration of rLZ-8 stimulates IFN-γ secretion. It is not only a good dietary supplement for humans but also an antibiotic alternative for animal additives for the prevention of virus or coccidia infection in field studies. Possible pharmaceutical applications per oral include immune-regulatory diseases. – IFN-γ Stimulant – Anti-viral – Antibiotic alternative – Anti-coccidia – Increase feed efficiency – US, TW, CN patent granted (US9950028, I589586, CN106232133A) | Simpson Biotech Co., Ltd. specializes in bio-fermentation development and commercialization: 1. Medicinal fungi for dietary supplements and early-stage drug discovery, specifically Hepasim®. 2. SimpsonPure health supplements portfolios. 3. Patented platform developing for recombinant protein expression and purification. We are seeking partnerships for the development of new recombinant proteins.
Sikich
Sikich LLP is a business and technology consultancy who’s close to 1,500 team members provide advisory, consulting, and technology services to clients in life sciences, manufacturing, professional services, and other industries. The company’s life sciences practice spans the industry and supports more than 200 life sciences clients, including biotechnology and biopharmaceutical companies, CROs, and lab diagnostic companies. As a leading life science technology consultant, we can help you streamline operations and ensure compliance, allowing stakeholders to do what they do best: develop new medicines for patients who need them. | At Sikich, we empower life sciences organizations through strategic planning, regulatory expertise, and digital modernization. From inception to commercialization, we specialize in planning, regulatory, quality, and compliance, leveraging cutting-edge technologies like Oracle NetSuite, Honeywell’s TrackWise Digital, and Kneat’s solutions to streamline operations and accelerate innovation. Our tailored approach combines deep industry knowledge with advanced digital tools, ensuring compliance, enhancing efficiency, and reducing time-to-market for life-changing therapies. A focus on built in audit trails, roles-based control and automated reporting ensure compliance with FDA 21 CFR Part 11, SOX and EU Annex 11. With a commitment to precision, integrity, and transformation, we help companies navigate complex regulatory landscapes and embrace the future of life sciences with confidence. Plan smarter. Modernize faster. Innovate with impact.